Hypermethylation of p15 promoter occurs in approximately 50% of patients with chronic myeloid leukemia (CML), AML, and acute lymphoblastic leukemia (ALL) and represents a key feature of the malignant progression of MDS [16]. The gene discussed is CDKN2B; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.